Age: 2.0
Sex: M
Vaccine: MMR, DTP, HIBV, IPV, MMR
Symptoms: Injury, Mental retardation severity unspecified, Nervous system disorder, Obesity, Pharyngitis
Clinical narrative: This case was considered medically important (OMIC). Information regarding Hib vaccine injection, manufacturer unk was received from medical records via an attorney regarding a male pt who received a fourth dose on 7/13/93 along with a third dose of polio vaccine and a fourth dose of DTP manufacturer unk. On unspecified dates the child developed autism, non progressive encephalopathy and developmental delay. The pts concurrent illness includes gastroesophageal reflux disease with a past history of maternal pre eclampsia toxemia requiring induction at 38 weeks. Indication for Hib vaccine was immunization. Product was administered on 7/13/1993. Dose regimen was 1 dose 1 time per day. Additional suspect medication include DTP, Polio, MMR II. Concomitant medication were not reported. Medical records received from an attorney, alleged that on unspecified dated, the pt having received a dose of Hib vaccine, along with other childhood vaccines, experienced autism, developmental delay, and non progressive encephalopathy. The pts outcome was unk. No additional information was available at the time of this report. This is in follow-up to report(s) previously submitted on 9/25/2006; 10/13/2006; 10/19/2006. Information has been received regarding a case in litigation concerning a minor male patient who was exposed to high levels of mercury from thimerosal through exposure to unspecified products. In addition, the patient was exposed to mercury from continually inhaling and ingesting industry mercury emissions from fossil fuel driven power plants. The mercury included in thimerosal laden products and power plant emissions together caused the patient to suffer from serious and permanent neurological injuries. The patient was exposed to airborne mercury vapor and mercury through food chain. The exposure to airborne mercury in the environment through inhalation, the food chain, and other sources contributed to the cumulative mercury toxicity and was a substantial factor in causing his neurological damage. It was noted that the patient had a heightened vulnerability to suffer neurological injuries from industrial mercury as a direct result of thimerosal exposure. As a direct and proximate cause of the toxic mercury exposure to the patient, minor male was caused to suffer serious and permanent neurological damage which include past and future mental, intellectual, developmental and neurological incapacity and associated learning disabilities, disorders and impairments. Follow-up information has been received from medical records concerning a 20 month old male born vaginally at term (EDD 19-DEC-1990) whose mother experienced toxaemia during pregnancy and who has a history chickenpox, colic, URI, gastroenteritis, GERD, hospitalization for right inguinal hernia, slight obesity, kidney failure, and epilepsy who vaccinated with a first and second dose of MMR II on 22-MAY-1992 and 22-AUG-1995. Concomitant vaccination on 22-AUG-1995 included a fifth dose of DTP (unspecified), a fourth dose of poliovirus vaccine live oral and a third dose of tuberculin(MONO-VACC TEST O.T.). Illness at the time of vaccination included tinea capitis. On 28-APR-1994 the patient was seen for a psychological evaluation and was diagnosed with hyperactivity, oppositional defiant behavior, language delay and separate anxiety. On 24-APR-1996 the patient was considered to be a child who had a non-progressive encephalopathy due to some type of organic brain problem. On 10-MAY-1996 the patient underwent an MRI of the brain which was normal. On 24-NOV-1999 the patient was diagnosed with Autism and was treated with PROZAC 1.5 CC every morning and RITALIN 1/2 tablet in the morning for one week then 1 table every morning and one in the afternoon. On 01-NOV-1999 it was noted that the patient had been diagnosed with Pervasive Developmental Delays and ADHD. It was noted that he had a history of seizures starting in 1995. On 01-NOV-1999 the patient was seen for a central auditory test. The results were consistent with a significant auditory processing disorder. On 03-APR-2001 it was noted that the patient was treated with PAXIL 10 mg daily. On 04-FEB-2002 it was noted that the patient was currently on therapy with ZOLOFT. On 27-MAR-2002 the patient was seen in the neurology clinic. It was reported that the patient could not be clearly diagnosed as having wither ASPERGER syndrome or high functioning autism. The language delay was more consistent with high functioning autism. It was noted that he may fall in the "gray zone" between the two diagnoses. It was noted that he was on therapy with ZOLOFT 50 mg q.h.s. and melatonin 2 mg( which was discontinued after this visit). On 17-MAY-2004 the patient was seen in follow-up at the neurology clinic for Autism, apparently high function. The patient' apgar scores were reported as 5 and 95. At the time of the report the patient's outcome was not recovered with the exception of seizure which was unknown. Follow-up information received on 12-SEP-2006 contained the following adverse experiences: diarrhea(approximately 20-AUG-1992), vomiting( 27-AUG-1992), sinusitis(14-SEP-1995), fall resulting in scalp laceration(13-JAN-1996), significant conductive hearing loss, particularly on right side(approximately 18-JUN-1996), adenoid hypertrophy(hospitalized:15-JUL-1996), cough( 20-AUG-1999), pharyngitis(23-AUG-1999), slightly obese(31-JAN-2002 ), poor sleep(25-NOV-2003), frequent urination(25-NOV-2003) and foul breath(onset unknown). Follow-up information from medical records indicated that on 24-OCT-1994 the patient underwent a speech evaluation. The results were as follows: auditory comprehension-57(50-65); expressive communication 69(62-76); total language score: 59 (50-68); age equivalent 1 year 10 months. Follow-up information received on 06-OCT-2006 contained the following adverse experience: fever (December 1998). Additional vaccine history included a first second and third dose of DTP (unspecified) on 29-MAR-1991, 03-JUN-1991, and 11-SEP-1991, respectively; a first dose of ACEL-IMUNE on 13-JUL-1993; a first, second and third dose of poliovirus vaccine live oral on 29-MAR-1991, 01-JUN-1991, and 13-JUL-1993; a first, second and third dose of HIBTITER on 29-MAR-1992, 03-JUN-1991, and 11-SEP-1991, respectively; a first dose of PROHIBIT on 13-JUL-1993; a first and second of tuberculin(MONO-VACC TEST O.T.) on 31-JAN-1992 and 13-JUL-1993. Upon internal review cumulative mercury toxicity, language delay, non-progressive encephalopathy, significant auditory processing disorder, pervasive developmental delays, ADHD, autism, and seizures were considered to be other important medical events. The patient's learning disability was considered to be disabling. No further information is available. All available medical records will be provided upon request.